• LAST PRICE
    0.6841
  • TODAY'S CHANGE (%)
    Trending Down-0.0159 (-2.2714%)
  • Bid / Lots
    0.6590/ 3
  • Ask / Lots
    0.7092/ 9
  • Open / Previous Close
    0.7850 / 0.7000
  • Day Range
    Low 0.6500
    High 0.7950
  • 52 Week Range
    Low 0.6500
    High 18.0000
  • Volume
    26,829
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 0.7
TimeVolumeAIMD
09:32 ET1080.785
10:13 ET49720.7001
11:45 ET1000.7
11:48 ET3000.699899
11:50 ET6990.795
12:39 ET1000.7
01:00 ET183990.6574
01:02 ET1000.65
01:08 ET4000.69585
01:09 ET10000.6841
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesAIMD
Ainos Inc
14.0M
-0.7x
---
United StatesMYMX
Mymetics Corp
13.3M
-2.3x
---
United StatesCRBP
Corbus Pharmaceuticals Holdings Inc
14.4M
-0.3x
---
United StatesEDSA
Edesa Biotech Inc
13.9M
-0.7x
---
United StatesVINC
Vincerx Pharma Inc
14.5M
-0.2x
---
United StatesGRAY
Graybug Vision Inc
14.4M
-0.4x
---
As of 2022-11-28

Company Information

Ainos, Inc. is engaged in developing biologics for the treatment of human and animal diseases. The Company is researching for the treatment of human disease indications, including Sjogren’s syndrome, thrombocytopenia, and other indications using interferon-alpha. The Company is also developing and manufacturing point-of-care testing rapid test kit products that include diagnostics for COVID-19, pneumonia, vaginal infection and helicobacter pylori bacterial infection. Its business units include Pharmaceutical, Medical Devices and Preventive Medicine Divisions. Pharmaceutical Division is focused on low-dose, orally administered lozenges containing the natural immune system activator interferon-alpha as a treatment for a variety of disease indications. Medical Device Division is developing an insulin pump and further development of point-of-care rapid test kits for the detection and diagnosis of human infections. Preventative Medicine Division is focused on SRNA-based therapeutics.

Contact Information

Headquarters
8880 Rio San Diego Drive, Ste. 800SAN DIEGO, CA, United States 92108
Phone
858-869-2986
Fax
---

Executives

Chairman of the Board, President, Chief Executive Officer
Chun-Hsien Tsai
Chief Financial Officer
Hui-Lan Wu
Executive Vice President - Operations
Lawrence Lin
Independent Director
Wen-Han Chang
Independent Director
Yao-Chung Chiang

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$14.0M
Revenue (TTM)
$2.5M
Shares Outstanding
20.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.04
EPS
$-1.03
Book Value
$1.06
P/E Ratio
-0.7x
Price/Sales (TTM)
5.6
Price/Cash Flow (TTM)
---
Operating Margin
-529.71%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.